CN111012736A - Application of sterile spray dressing for blocking novel coronavirus 2019-nCov - Google Patents
Application of sterile spray dressing for blocking novel coronavirus 2019-nCov Download PDFInfo
- Publication number
- CN111012736A CN111012736A CN202010086854.1A CN202010086854A CN111012736A CN 111012736 A CN111012736 A CN 111012736A CN 202010086854 A CN202010086854 A CN 202010086854A CN 111012736 A CN111012736 A CN 111012736A
- Authority
- CN
- China
- Prior art keywords
- spray dressing
- lht
- sterile spray
- bioactive peptide
- sterile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 53
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 27
- 230000000903 blocking effect Effects 0.000 title claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 230000000975 bioactive effect Effects 0.000 claims abstract description 38
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 16
- 210000000214 mouth Anatomy 0.000 claims abstract description 15
- 239000011241 protective layer Substances 0.000 claims abstract description 8
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 6
- 210000001339 epidermal cell Anatomy 0.000 claims abstract description 6
- 210000005260 human cell Anatomy 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 5
- 101710085938 Matrix protein Proteins 0.000 claims abstract description 5
- 101710127721 Membrane protein Proteins 0.000 claims abstract description 5
- 210000000234 capsid Anatomy 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 241000003595 Aurantiochytrium limacinum Species 0.000 claims description 5
- 241000283074 Equus asinus Species 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 4
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 108090000565 Capsid Proteins Proteins 0.000 claims description 3
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- -1 alanine (Ala) Chemical class 0.000 claims 1
- 239000002075 main ingredient Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 241000233671 Schizochytrium Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000009351 contact transmission Effects 0.000 description 2
- 230000009365 direct transmission Effects 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to application of an aseptic spray dressing, in particular to application of an aseptic spray dressing for blocking a novel coronavirus 2019-nCov. The main component of the sterile spray dressing is bioactive peptide LHT which is sprayed into the nasal cavity or the oral cavity to form a protective layer, when viruses contact the protective layer of the nasal cavity or the oral cavity, the bioactive peptide LHT is rapidly combined with capsid M protein of the viruses, so that the bioactive peptide LHT is blocked outside the body before contacting human cells. On the other hand, after the main component of the sterile spray dressing, namely the bioactive peptide LHT, is sprayed into the nasal cavity or the oral cavity, the bioactive peptide LHT can also be combined with the exposed parts of angiotensin converting enzyme ACE and ACE2 protease on the epidermal cell membrane of the human body, so that the approach of the novel coronavirus to invade cells is blocked.
Description
Technical Field
The invention relates to application of an aseptic spray dressing, in particular to application of an aseptic spray dressing for blocking a novel coronavirus 2019-nCov.
Background
2019 novel coronavirus (2019-nCoV), and named by world health organization in 12 months 1 and 2020. Coronaviruses belong to the phylogenetic group of Coronaviridae (Coronaviridae) coronaviruses (Coronavirus). Viruses of the genus coronavirus are positive-stranded single-stranded RNA viruses with an envelope structure that has three proteins: spike glycoprotein (S), small Envelope glycoprotein (E), and Membrane glycoprotein (M). The S protein recognizes and combines with a host cell surface receptor and mediates fusion of a virus envelope and a cell membrane; the M protein is involved in the formation and budding of the virus envelope. Research shows that the novel coronavirus is capable of recognizing angiotensin converting enzyme ACE and ACE2 protease on cell membranes of bronchial epithelial cells and alveolar cells of human bodies through the S protein of the novel coronavirus to be combined and invaded into the human bodies, so that pneumonia is infected. 2019 the novel coronavirus is the 7 th coronavirus which is known to infect human, and the remaining 6 are HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV, respectively.
After a person is infected with 2019 novel coronavirus, acute infectious pneumonia can be caused, and the initial symptoms of the patient are fever, weakness and dry cough, and severe manifestations such as dyspnea gradually appear. The prognosis is good in most patients and acute respiratory distress syndrome or septic shock may occur in some severe cases and even death. 2019 the pneumonia caused by the novel coronavirus is high in infectivity. Based on the current epidemiological investigation, the latent period is 1-14 days, the latent period of a few infected persons exceeds 14 days, the latent period is infectious, and asymptomatic infected persons can also become the source of infection. The 2019 novel coronavirus transmission routes which can be determined at present are mainly direct transmission, aerosol transmission and contact transmission. Direct transmission refers to infection caused by sneezing, coughing, speaking droplets and direct inhalation of exhaled air in close proximity; aerosol transmission refers to the mixing of droplets in the air to form an aerosol which causes infection after inhalation; contact transmission refers to the condition that droplets are deposited on the surface of an article and contact with mucous membranes such as oral cavity, nasal cavity, eyes and the like after contacting with contaminated hands, so that infection is caused. However, currently, there are very limited medical products and drugs that can safely and effectively block the infection of the novel coronavirus.
Disclosure of Invention
In order to make up for the defects, the invention aims to provide the application of the sterile spray dressing for blocking the novel coronavirus 2019-nCov. The sterile spray dressing is sprayed into the nasal cavity or the oral cavity to form a protective layer, which can prevent the invasion of external substances such as viruses, and has no toxic or side effect, safety and reliability.
The invention discloses an application of a sterile spray dressing for blocking a novel coronavirus 2019-nCov, and the technical scheme adopted for solving the technical problem comprises the following contents:
the aseptic spray dressing contains bioactive peptide LHT and auxiliary materials, wherein the addition amount of the bioactive peptide LHT is 0.1-0.5%, the auxiliary materials contain 0.1-1% of thickening agent, 0.01-0.5% of preservative, 0.01-0.2% of citric acid, 0.3-0.9% of sodium chloride, 0.1-1.5% of disodium hydrogen phosphate, 0.01-0.06% of disodium ethylene diamine tetraacetate, and the volume of purified water is up to 100%.
The thickener is preferably one of hydroxyethyl cellulose and sodium carboxymethyl cellulose.
The antiseptic is preferably one or more of methyl hydroxybenzoate, sodium hydroxybenzoate and ethylparaben.
The application of the sterile spray dressing is characterized in that the bioactive peptide LHT contained in the sterile spray dressing is derived from a mixture of enzymatic hydrolysis of bioactive peptide of schizochytrium limacinum and donkey serum protein.
The bioactive peptide of the microalgae schizochytrium sourced from the ocean is obtained by extracting DHA (docosahexaenoic acid) from algal dregs obtained after fermenting the microalgae schizochytrium sourced from the ocean, degrading by protease, separating and purifying, and can be combined with capsid M protein of coronavirus, so that the bioactive peptide is blocked outside the body before contacting human cells to prevent the bioactive peptide from entering the human body.
The microalgae schizochytrium limacinum is a new food raw material approved by the Ministry of health of the people's republic of China (No. 3 in 2010), adopts the international leading bioinformatics technology, and is used for target positioning and separation of active peptide LHT (LHT), and is a main raw material for producing sterile spray dressing, and the safety, the non-toxicity and the reliability of the microalgae schizochytrium limacinum are proved by the national authority.
The donkey serum albumin has been proved by research that peptides obtained by enzymolysis of donkey serum proteins have an inhibitory effect on angiotensin converting enzyme and can be combined with exposed external parts of angiotensin converting enzyme ACE and ACE2 protease on human epidermal cell membranes, so that the approach of novel coronavirus invading cells is blocked.
In addition, the ethylene diamine tetraacetic acid disodium in the sterile spray dressing has research to show that the aseptic spray dressing also has the effect of blocking coronavirus.
The invention also provides application of the sterile spray dressing for blocking the novel coronavirus 2019-nCov.
The application of the sterile spray dressing is characterized in that the amino acids contained in the bioactive peptide LHT contained in the sterile spray dressing are alanine (Ala), arginine (Arg), aspartic acid (Asp), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), asparagine (Asn) and cysteine (Cys).
The application of the sterile spray dressing is characterized in that the molecular formula of bioactive peptide contained in the bioactive peptide LHT contained in the sterile spray dressing is C43H76N10O18,C29H47N6O9,C33H60N7O9,C28H49N6O8S。
The sterile spray dressing is applied to II and III medical appliance products.
The sterile spray dressing is used for the oral cavity or the nasal cavity.
The bioactive peptide LHT of the aseptic spray dressing is derived from a mixture of the enzymatic hydrolysis bioactive peptide of the marine microalgae schizochytrium limacinum and the enzymatic hydrolysis of donkey serum protein, has good synergistic effect, and can block viruses from invading human bodies from two aspects:
on one hand: the bioactive peptide LHT is combined with the virus capsid protein Mpro to play a barrier role to the human body:
the sterile spray dressing containing the bioactive peptide LHT is sprayed into the nasal cavity or the oral cavity to form a protective layer, and when viruses contact the protective layer of the nasal cavity or the oral cavity, the bioactive peptide LHT is rapidly combined with capsid M protein of the viruses, so that the bioactive peptide LHT is blocked outside the body before contacting human cells. The protective layer acts as a barrier to viruses, blocking their entry into the body.
On the other hand: the bioactive peptide LHT can compete with the virus capsid protein to combine with the protein outside the human epidermal cell membrane to block the approach of virus invading the human cells, and plays a barrier role to the human body:
the sterile spray dressing containing bioactive peptide LHT can be sprayed into nasal cavity or oral cavity, and can also be combined with exposed external parts of angiotensin converting enzyme ACE and ACE2 protease on human epidermal cell membrane, so that the approach of novel coronavirus invading cell is blocked. Namely, a barrier is formed by the sterile spray dressing and the outside of human cells together, and the novel coronavirus is blocked from invading the human body.
Detailed Description
In order to make the technical solution of the present invention more clearly known to those skilled in the art, the following combination tool
The embodiments of the present invention will be described in detail.
Example 1
0.18 percent of bioactive peptide LHT, 0.3 percent of sodium carboxymethylcellulose, 0.02 percent of sodium methyl hydroxybenzoate, 0.12 percent of citric acid, 0.48 percent of sodium chloride, 1.4 percent of disodium hydrogen phosphate, 0.05 percent of ethylene diamine tetraacetic acid and purified water with constant volume of 100 percent.
Example 2
0.18 percent of bioactive peptide LHT, 0.3 percent of sodium carboxymethylcellulose, 0.02 percent of sodium methyl hydroxybenzoate, 0.12 percent of citric acid, 0.48 percent of sodium chloride, 0.14 percent of disodium hydrogen phosphate, 0.05 percent of ethylene diamine tetraacetic acid and purified water with constant volume of 100 percent.
Example 3
0.18 percent of bioactive peptide LHT, 0.3 percent of hydroxyethyl cellulose, 0.02 percent of sodium methyl hydroxybenzoate, 0.12 percent of citric acid, 0.48 percent of sodium chloride, 0.14 percent of disodium hydrogen phosphate, 0.05 percent of disodium ethylene diamine tetraacetate and purified water with constant volume of 100 percent.
Example 4 sterile spray dressing experience survey
30 volunteers were recruited, and each volunteer sprayed the sterile spray dressing prepared in example 1, example 2 and example 3 to the oral cavity and the nasal cavity respectively for sensory evaluation, and the specific experience effects were as follows: 30 volunteers of the sterile spray dressings prepared in examples 1 to 3 all felt a slightly salty taste, wherein 1 volunteer felt that the sterile spray dressings of examples 1 and 2 had sensitive and irritating manifestations when sprayed into the nasal cavity, and 30 volunteers of the sterile spray dressing of example 3 had no sensitive and irritating manifestations when sprayed into the oral cavity and the nasal cavity.
The embodiment described above is not all embodiments of the present invention, and the detailed description of the embodiment is not intended to limit the present invention, but only shows selected embodiments of the present invention. Those skilled in the art can now appreciate that many changes can be made to the embodiments described above.
Claims (10)
1. The application of the sterile spray dressing for blocking the novel coronavirus 2019-nCov is characterized in that the sterile spray dressing contains bioactive peptide LHT and auxiliary materials, wherein the addition amount of the bioactive peptide LHT is 0.1-0.5%, the auxiliary materials contain 0.1-1% of a thickening agent, 0.01-0.5% of a preservative, 0.01-0.2% of citric acid, 0.3-0.9% of sodium chloride, 0.1-1.5% of disodium hydrogen phosphate, 0.01-0.06% of disodium ethylene diamine tetraacetate and a proper amount of purified water, the thickening agent is preferably one of hydroxyethyl cellulose and sodium carboxymethyl cellulose, and the preservative is preferably one or more of methyl hydroxybenzoate, sodium hydroxybenzoate and ethylparaben.
2. The use of the sterile spray dressing according to claim 1, wherein the bioactive peptide LHT contained in the sterile spray dressing is derived from a mixture of enzymatic hydrolysis active peptide of schizochytrium limacinum and donkey serum protein.
3. The use of the sterile spray dressing according to claims 1-2, wherein the bioactive peptide LHT contained in the sterile spray dressing contains amino acids such as alanine (Ala), arginine (Arg), aspartic acid (Asp), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), valine (Val), asparagine (Asn), cysteine (Cys).
4. The use of sterile spray dressing according to claims 1-3, wherein the bioactive peptide LHT contained in the sterile spray dressing has a bioactive peptide formula C43H76N10O18,C29H47N6O9,C33H60N7O9,C28H49N6O8S。
5. The use of the sterile spray dressing of claims 1-4, wherein the sterile spray dressing is used in a class II, III medical device product.
6. The use of the sterile spray dressing according to claims 1-5, wherein the sterile spray dressing is for use in the oral or nasal cavity.
7. The use of the sterile spray dressing according to claims 1-6, wherein the main component of the sterile spray dressing is bioactive LHT which can also bind to viruses, inactivate the viruses and shield the viruses from the outside of the human body.
8. The use of the sterile spray dressing according to claim 7, wherein the main component of the sterile spray dressing is bioactive peptide LHT which forms a protective layer after being sprayed into the nasal cavity or the oral cavity, and when viruses contact the protective layer of the nasal cavity or the oral cavity, the bioactive peptide LHT is rapidly combined with capsid M protein of the viruses, so that the bioactive peptide LHT is blocked outside the human body before contacting human body cells.
9. The use of the sterile spray dressing according to claims 1-6, wherein the main component of the sterile spray dressing is bioactive peptide LHT which can compete with virus capsid protein to bind with protein outside human epidermal cell membrane, thereby blocking the way of virus invading human cells.
10. The use of the sterile spray dressing according to claim 9, wherein the main ingredient of the sterile spray dressing is bioactive peptide LHT which is sprayed into nasal cavity or oral cavity and can be combined with the exposed external parts of angiotensin converting enzyme ACE and ACE2 protease on human epidermal cell membrane, so that the path of new coronavirus invading cells is blocked.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010086854.1A CN111012736A (en) | 2020-02-11 | 2020-02-11 | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010086854.1A CN111012736A (en) | 2020-02-11 | 2020-02-11 | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111012736A true CN111012736A (en) | 2020-04-17 |
Family
ID=70203418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010086854.1A Pending CN111012736A (en) | 2020-02-11 | 2020-02-11 | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111012736A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111474350A (en) * | 2020-04-23 | 2020-07-31 | 中国林业科学研究院林业研究所 | Kit for detecting coronavirus S1 antigen and non-diagnosis-purpose detection method thereof |
IT202100016037A1 (en) * | 2021-06-18 | 2021-09-18 | Antonio Bianchi | SPRAY FORMULATION FOR NASAL/ORAL USE WITH ACTIVITY AGAINST RESPIRATORY CORONAVIRUSES |
WO2022084931A1 (en) * | 2020-10-23 | 2022-04-28 | Antonio Bianchi | Spray formulation for nasal/oral use with activity against respiratory coronaviruses and in particular the sars-cov-2 virus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110195449A1 (en) * | 2009-12-28 | 2011-08-11 | Martek Biosciences Corporation | Recombinant Thraustochytrids that Grow on Sucrose, and Compositions, Methods of Making, and Uses Thereof |
CN105555290A (en) * | 2013-05-10 | 2016-05-04 | 莱顿大学学术医院以Lumc的名义运作 | Antimicrobial peptide |
CN106755229A (en) * | 2016-11-24 | 2017-05-31 | 福州大学 | A kind of preparation method of schizochytrium limacinum algae cake protein Peptides |
WO2017197542A1 (en) * | 2016-05-20 | 2017-11-23 | 浙江红雨医药用品有限公司 | Antibacterial dressing, and preparation method and use thereof |
-
2020
- 2020-02-11 CN CN202010086854.1A patent/CN111012736A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110195449A1 (en) * | 2009-12-28 | 2011-08-11 | Martek Biosciences Corporation | Recombinant Thraustochytrids that Grow on Sucrose, and Compositions, Methods of Making, and Uses Thereof |
CN105555290A (en) * | 2013-05-10 | 2016-05-04 | 莱顿大学学术医院以Lumc的名义运作 | Antimicrobial peptide |
WO2017197542A1 (en) * | 2016-05-20 | 2017-11-23 | 浙江红雨医药用品有限公司 | Antibacterial dressing, and preparation method and use thereof |
CN106755229A (en) * | 2016-11-24 | 2017-05-31 | 福州大学 | A kind of preparation method of schizochytrium limacinum algae cake protein Peptides |
Non-Patent Citations (4)
Title |
---|
GEETANJALI MEHER,等: "Membrane Cholesterol Modulates Oligomeric Status and Peptide-Membrane Interaction of Severe Acute Respiratory Syndrome Coronavirus Fusion Peptide", 《J. PHYS. CHEM. B》 * |
崔春: "《食物蛋白质控制酶解技术》", 30 June 2018, 中国轻工业出版社 * |
李青叶: "驴血清蛋白酶解物生产工艺的优化及活性初步研究", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技Ⅰ辑》 * |
梁双振: "源于海洋微藻生物活性肽的研究", 《中国优秀博硕士学位论文全文数据库(硕士) 基础科学辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111474350A (en) * | 2020-04-23 | 2020-07-31 | 中国林业科学研究院林业研究所 | Kit for detecting coronavirus S1 antigen and non-diagnosis-purpose detection method thereof |
CN111474350B (en) * | 2020-04-23 | 2023-07-07 | 中国林业科学研究院林业研究所 | Kit for detecting coronavirus S1 antigen and detection method for non-diagnostic purpose thereof |
WO2022084931A1 (en) * | 2020-10-23 | 2022-04-28 | Antonio Bianchi | Spray formulation for nasal/oral use with activity against respiratory coronaviruses and in particular the sars-cov-2 virus |
IT202100016037A1 (en) * | 2021-06-18 | 2021-09-18 | Antonio Bianchi | SPRAY FORMULATION FOR NASAL/ORAL USE WITH ACTIVITY AGAINST RESPIRATORY CORONAVIRUSES |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111012736A (en) | Application of sterile spray dressing for blocking novel coronavirus 2019-nCov | |
DK180405B1 (en) | Novel trypsin isoforms and their use | |
Siniavin et al. | Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2 | |
JP2021509809A (en) | Peptides with protease activity for use in the treatment or prevention of coronavirus infections | |
CN111728963A (en) | Application of copper gluconate in preparing medicine for preventing or treating novel coronavirus infection | |
WO2021222965A1 (en) | Mannose-binding lectin for treatment or prophylaxis of infectious diseases | |
US11304989B2 (en) | Peptides for use in the treatment of viral infections | |
Li et al. | SARS-CoV-2 and emerging variants: unmasking structure, function, infection, and immune escape mechanisms | |
Pineda et al. | Quinacrine as a potential treatment for COVID-19 virus infection. | |
EP4138891A1 (en) | Peptides for the treatment of covid-19 | |
US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
US5900401A (en) | Remedy for respiratory-tract viral disease | |
CA2792727C (en) | Therapy for influenza like illness | |
US20240000901A1 (en) | Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection | |
Kobayashi-Sakamoto et al. | Lactoferrin as a Possible Preventive and Therapeutic Agent Against SARS-CoV-2 Infection | |
Priadharsini et al. | Lung Recruitability in COVID-19 | |
Tavakoli et al. | Oral symptoms of patients tested positive for COVID-19 with mild severity-a cross-sectional study | |
MXPA96004207A (en) | Novedous remedy for tractor pyrrato viral disease | |
CN104311644A (en) | Polypeptide, method for improving stability of polypeptide, pharmaceutical composition and application of polypeptide in preparation of medicaments | |
TW202334430A (en) | Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections | |
EP4331571A1 (en) | Formulations of ace2-igm fusion proteins | |
JP2023006351A (en) | antiviral composition | |
JP2023526200A (en) | Compatible Solutes for Prevention or Treatment of SARS-CoV-2 Infection | |
EP1500662A2 (en) | Stabilizing peptides | |
Facilitates | The Fusion Glycoprotein of Human |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200417 |
|
WD01 | Invention patent application deemed withdrawn after publication |